Top

Published in:

01-11-2014 | Research Letter

Ultrasound-guided percutaneous ethanol injection in papillary thyroid cancer metastatic lymph-nodes

Authors: Guia Vannucchi, Danila Covelli, Michela Perrino, Simone De Leo, Laura Fugazzola

Published in: Endocrine | Issue 2/2014

Abstract

Post-operative neck nodal metastases are detected in 9–20 % of papillary thyroid cancer (PTC). Ultrasound-guided ethanol injection (UPEI) has been used with promising results in the treatment of PTC patients with limited number of lymph-node metastases. Clinical Case: We report the imaging and biochemical documentation of UPEI results in four metastatic neck lymph-nodes of papillary thyroid-cancer. A significant reduction both in the diameter of the lymph-nodes and in the serum thyroglobulin levels were observed in all cases and have been reported in a step-by-step sequence. Conclusion: the UPEI treatment is a simple and suitable tool for the treatment of PTC cervical lymph-node metastases.

S.K. Grebe, I.D. Hay, Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg. Oncol. Clin. N. Am. 5, 43–63 (1996)PubMed

K.G. Schuff, Management of recurrent/persistent papillary thyroid carcinoma: efficacy of the surgical option. J. Clin. Endocrinol. Metab. 96, 2038–2039 (2011)PubMedCrossRef

J.H. Yim, W.B. Kim, E.Y. Kim, W.G. Kim, T.Y. Kim, J.S. Ryu, G. Gong, S.J. Hong, Y.K. Shong, The outcomes of first reoperation for locoregionally recurrent/persistent papillary thyroid carcinoma in patients who initially underwent total thyroidectomy and remnant ablation. J. Clin. Endocrinol. Metab. 96, 2049–2056 (2011)PubMedCrossRef

B.D. Lewis, I.D. Hay, J.W. Charboneau, B. McIver, C.C. Reading, J.R. Goellner, Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. AJR Am. J. Roentgenol. 178, 699–704 (2002)PubMedCrossRef

J.M. Monchik, G. Donatini, J. Iannuccilli, D.E. Dupuy, Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma. Ann. Surg. 244, 296–304 (2006)PubMedCrossRefPubMedCentral

C.Y. Lim, J.S. Yun, J. Lee, K.H. Nam, W.Y. Chung, C.S. Park, Percutaneous ethanol injection therapy for locally recurrent papillary thyroid carcinoma. Thyroid 17, 347–350 (2007)PubMedCrossRef

B.M. Kim, M.J. Kim, E.K. Kim, S.I. Park, C.S. Park, W.Y. Chung, Controlling recurrent papillary thyroid carcinoma in the neck by ultrasonography-guided percutaneous ethanol injection. Eur. Radiol. 18, 835–842 (2008)PubMedCrossRef

A. Heilo, E. Sigstad, K.H. Fagerlid, O.I. Håskjold, K.K. Grøholt, A. Berner, T. Bjøro, L.H. Jørgensen, Efficacy of ultrasound-guided percutaneous ethanol injection treatment in patients with a limited number of metastatic cervical lymph nodes from papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 96, 2750–2755 (2011)PubMedCrossRef

Y.M. Sohn, S.W. Hong, E.K. Kim, M.J. Kim, H.J. Moon, S.J. Kim, E.J. Son, J.Y. Kwak, Complete eradication of metastatic lymph node after percutaneous ethanol injection therapy: pathologic correlation. Thyroid 19, 317–319 (2009)PubMedCrossRef

10.

I.D. Hay, R.A. Lee, C. Davidge-Pitts, C.C. Reading, J.W. Charboneau, Long-term outcome of ultrasound-guided percutaneous ethanol ablation of selected “recurrent” neck nodal metastases in 25 patients with TNM stages III or IVA papillary thyroid carcinoma previously treated by surgery and 131I therapy. Surgery 154(6), 1448–1454 (2013)PubMedCrossRef

Title: Ultrasound-guided percutaneous ethanol injection in papillary thyroid cancer metastatic lymph-nodes
Authors: Guia Vannucchi
Danila Covelli
Michela Perrino
Simone De Leo
Laura Fugazzola
Publication date: 01-11-2014
Publisher: Springer US
Published in: Endocrine / Issue 2/2014
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-014-0215-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status

Prevention of macrovascular disease in patients with short-duration type 2 diabetes by multifactorial target control: an 8-year prospective study

Pro: endoscopic endonasal transsphenoidal pituitary surgery is superior to microscope-based transsphenoidal surgery

Contribution of protein kinase Cα in the stimulation of insulin by the down-regulation of Cavβ subunits

Tumor-like pyogenic liver abscess caused by Klebsiella pneumoniae in diabetes

Sustained high levels of serum leptin rather than IL-6 observed in patients with postpartum thyroiditis during their first postpartum year

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials